Oram DH - Search Results

1

Long-term follow-up of gonadotrophin-releasing hormone analog treatment for recurrent endometrial cancer.

Jeyarajah AR, Gallagher CJ, Blake PR, Oram DH, Dowsett M, Fisher C, Oliver RT. Jeyarajah AR, et al. Among authors: oram dh. Gynecol Oncol. 1996 Oct;63(1):47-52. doi: 10.1006/gyno.1996.0276. Gynecol Oncol. 1996. PMID: 8898167 Clinical Trial.

2

Increased mortality in postmenopausal women with serum CA125 elevation.

Jeyarajah AR, Ind TE, MacDonald N, Skates S, Oram DH, Jacobs IJ. Jeyarajah AR, et al. Among authors: oram dh. Gynecol Oncol. 1999 May;73(2):242-6. doi: 10.1006/gyno.1999.5350. Gynecol Oncol. 1999. PMID: 10329041 Clinical Trial.

3

A new treatment for endometrial cancer with gonadotrophin releasing-hormone analogue.

Gallagher CJ, Oliver RT, Oram DH, Fowler CG, Blake PR, Mantell BS, Slevin ML, Hope-Stone HF. Gallagher CJ, et al. Among authors: oram dh. Br J Obstet Gynaecol. 1991 Oct;98(10):1037-41. doi: 10.1111/j.1471-0528.1991.tb15343.x. Br J Obstet Gynaecol. 1991. PMID: 1751436

4

Hormonal therapy in advanced or recurrent endometrial cancer.

Kokka F, Brockbank E, Oram D, Gallagher C, Bryant A. Kokka F, et al. Cochrane Database Syst Rev. 2010 Dec 8;2010(12):CD007926. doi: 10.1002/14651858.CD007926.pub2. Cochrane Database Syst Rev. 2010. PMID: 21154390 Free PMC article. Review.

5

Model for the molecular genetic diagnosis of endometrial cancer using K-ras mutation analysis.

Al-Jehani RM, Jeyarajah AR, Hagen B, Hogdall EV, Oram DH, Jacobs IJ. Al-Jehani RM, et al. Among authors: oram dh. J Natl Cancer Inst. 1998 Apr 1;90(7):540-2. doi: 10.1093/jnci/90.7.540. J Natl Cancer Inst. 1998. PMID: 9539251 No abstract available.

6

Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women.

Jeyarajah AR, Ind TE, Skates S, Oram DH, Jacobs IJ. Jeyarajah AR, et al. Among authors: oram dh. Cancer. 1999 May 1;85(9):2068-72. doi: 10.1002/(sici)1097-0142(19990501)85:9<2068::aid-cncr25>3.0.co;2-8. Cancer. 1999. PMID: 10223249 Clinical Trial.

7

Vulval cancer: what is an adequate surgical margin?

Balega J, Butler J, Jeyarajah A, Oram D, Shepherd J, Faruqi A, Singh N, Reynolds K. Balega J, et al. Eur J Gynaecol Oncol. 2008;29(5):455-8. Eur J Gynaecol Oncol. 2008. PMID: 19051811

8

Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery.

Saha A, Varughese M, Gallagher CJ, Orphanos G, Wilson P, Oram D, Jeyarajah A, Reynolds K, Shepherd J, McCormack M, Olaitan A, McDonald N, Mould T, McNeish I, Ledermann JA. Saha A, et al. Int J Gynecol Cancer. 2012 May;22(4):566-72. doi: 10.1097/IGC.0b013e318247727f. Int J Gynecol Cancer. 2012. PMID: 22426404

9

Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer.

Rockall AG, Sohaib SA, Harisinghani MG, Babar SA, Singh N, Jeyarajah AR, Oram DH, Jacobs IJ, Shepherd JH, Reznek RH. Rockall AG, et al. Among authors: oram dh. J Clin Oncol. 2005 Apr 20;23(12):2813-21. doi: 10.1200/JCO.2005.07.166. J Clin Oncol. 2005. PMID: 15837995 Clinical Trial.

10

The role of ultrasound and tumour markers in the early detection of ovarian cancer.

Oram DH, Jeyarajah AR. Oram DH, et al. Br J Obstet Gynaecol. 1994 Nov;101(11):939-45. doi: 10.1111/j.1471-0528.1994.tb13035.x. Br J Obstet Gynaecol. 1994. PMID: 7999723 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

75 results

Search Page

Filters